CompletedNCT00485550
Atomoxetine alone or with methylphenidate for children with ADHD
About this title
Read the official source — NCT00485550Medication studyAges 6–12United States
Understand this study
Who was this study for?
Listed age limits: 6 years to 12 years.
- Listed locations
- ScottsdaleSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJanuary 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 14
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 6 Years to 12 Years
- Official registry ID
- NCT00485550
- Official title
Show the full official title
A Randomized, Double-Blind Comparison of Atomoxetine Hydrochloride Augmented With Either Extended-Release Methylphenidate Hydrochloride (Concerta-TM) or Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) Who Have Not Responded to Stimulant Mono Therapy
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Scottsdale
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including Atomoxetine Hydrochloride, Methylphenidate Hydrochloride and Placebo.
Who was this study for?
Listed age limits: 6 years to 12 years.
